AI, Future Human Health & Disease ‘What Are We Facing’?
.jpeg)
.jpeg)
A global health conversation for
today before tomorrow becomes a diagnosis
Artificial intelligence is
rapidly changing how people work, learn, communicate, make decisions and access
information. The question is not whether AI is “good” or “bad.” The important
public-health question is:
As human exposure to AI and
digital environments increases, what changes in our brain, behaviour, sleep,
physical activity and metabolic health should we detect early — before they
become serious health problems?
The World Health Organization is
already calling for longitudinal research into the effects of generative AI and
digital environments on mental health and wellbeing. WHO has specifically
identified concerns involving excessive use, isolation, sleep, sedentary
behaviour, anxiety and depression, while emphasizing that the long-term effects
of generative AI are still insufficiently understood.
World Health Organization +1
🧠 THE WARNING MAY NOT
BEGIN WITH A DIAGNOSIS
It may begin with small changes
that people dismiss:
“I can't concentrate like
before.”
“I keep forgetting things.”
“I feel mentally tired.”
“I am becoming more easily
irritated.”
“My sleep isn't what it used to
be.”
“I spend too much time on
screens.”
“I don't feel like meeting people
anymore.”
These are symptoms or risk
indicators—not proof of disease.
That distinction is crucial.
WHO identifies memory problems,
confusion, mood changes, social withdrawal and difficulties with thinking among
possible early manifestations associated with cognitive impairment and
dementia, while also identifying modifiable risk factors such as physical
inactivity, poor sleep, diabetes, hypertension, obesity and social isolation.
World Health Organization
https://www.who.int/news-room/fact-sheets/detail/dementia?utm_source=chatgpt.com
So why wait until someone becomes
a patient?
.jpeg)
The better public-health approach
is:
NOTICE → MEASURE → ACT → MONITOR
→ SEEK MEDICAL CARE WHEN NEEDED
🌿 WHERE DOES KESUM FIT?
This is where KESUM (Persicaria
minor / Biokesum®) becomes an interesting research-supported brain-health
candidate.
A randomized, double-blind,
placebo-controlled human study involving older adults with mild cognitive
impairment found that six months of Biokesum® supplementation was associated
with significant improvements in:
Visual memory
Tension
Anger
Confusion
Total negative mood subscales
The researchers concluded that
Biokesum® potentially improved visual memory, negative mood, BDNF and
triglycerides.
PubMed Central (PMC) +1
https://pmc.ncbi.nlm.nih.gov/articles/PMC7574246/?utm_source=chatgpt.com
The reported changes included
approximately −18.7% confusion, −30.91% tension, −52.95% anger, −33.43% total
negative mood subscales and −19.05% triglycerides, while BDNF increased 2.03%
in the Biokesum® group.
PubMed Central (PMC) https://pmc.ncbi.nlm.nih.gov/articles/PMC7574246/?utm_source=chatgpt.com
That gives us an important
scientific pathway:
EARLY SYMPTOM → BIOMARKER →
INTERVENTION → MONITORING
Memory / confusion
↓
Cognitive assessment
Stress / negative mood
↓
Mood assessment
Brain-health pathway
↓
BDNF monitoring
Metabolic risk
↓
Triglyceride monitoring
Then: lifestyle + medical
assessment + evidence-supported interventions where appropriate.
BUT KESUM SHOULD NOT BE PRESENTED
AS A CURE
This is actually what makes the
message more credible internationally.
The 2020 trial was conducted in
36 Malaysian adults aged 60–75 with MCI, with 30 completing the intervention.
It provides human clinical evidence for particular measured outcomes but it
does not establish that KESUM prevents Alzheimer's disease, dementia, or
AI-related disease.
PubMed
https://pubmed.ncbi.nlm.nih.gov/33076878/
Therefore, the strongest message
is:
“Don't wait for disease.
Recognise the early warning signs, monitor brain health and act early.”
And:
“KESUM is a clinically studied
botanical candidate for brain-health support—not a replacement for diagnosis or
medical treatment.”
That is scientifically much
stronger than making a disease-prevention claim.
🌍 THE 2026–2056 QUESTION
This could become a long-term
international community-health story:
2026
Establish the baseline.
2030
Measure changes in AI/digital
exposure, sleep, physical activity, mental health and cognition.
2035
Compare populations by age, sex
and country.
2040
Determine whether persistent
digital/AI behaviours are associated with measurable long-term health changes.
2045
Track people who showed early
symptoms versus those who did not.
2050
Examine whether early
interventions changed outcomes.
2056
After 30 years, we may finally
have robust longitudinal evidence showing which relationships were genuine,
which were temporary and which were unrelated to AI.
That is the scientific experiment
the world has not yet completed.
🧠 THE KESUM QUESTION
.jpeg)
Instead of asking:
“Can KESUM prevent dementia?”
Ask the scientifically testable
question:
“Can early identification of
cognitive and mood changes, combined with lifestyle intervention and
evidence-supported nutritional approaches such as Biokesum®, help maintain
brain-health indicators and potentially delay progression in at-risk
individuals?”
That question can be tested.
And BDNF gives us one measurable
biological pathway to investigate, rather than relying only on people's
subjective feelings.
THE MESSAGE TO THE WORLD
AI is advancing faster than our
understanding of its long-term effects on human health.
We should not wait 20 or 30 years
to discover that early warning signs were ignored.
Memory changes.
Confusion.
Stress.
Negative mood.
Poor sleep.
Reduced physical activity.
Social withdrawal.
Metabolic changes.
These should be noticed, measured
and investigated early.
KESUM — Persicaria minor /
Biokesum® — already has human clinical research showing improvements in
selected memory, mood, BDNF and triglyceride outcomes among older adults with
MCI.
PubMed Central (PMC)
https://pmc.ncbi.nlm.nih.gov/articles/PMC7574246/?utm_source=chatgpt.com
The opportunity now is not to
claim a cure.
The opportunity is to investigate
whether early brain-health support can help people stay healthier for longer.
Don't wait until symptoms become
a diagnosis.
NOTICE EARLY. MONITOR. ACT.
Science First. Everything
Follows.
This framing also aligns with the
2026 WHO approach to dementia risk reduction, which emphasizes action before
dementia develops including cognitive stimulation, physical activity,
management of cardiometabolic risks and other modifiable factors. WHO estimates
that up to 45% of dementia risk is attributable to potentially modifiable
factors, while stressing that risk reduction is not the same as guaranteeing
prevention.
World Health Organization +1
.jpeg)
.jpeg)
.jpeg)
A little note 🩷
Still available for
now.
While stocks last.
WHILE STOCKS LAST
WHILE STOCKS LAST
WHILE STOCKS LAST
No comments:
Post a Comment